ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Reconyl

Its studies are mostly in Cough, led by Dexa Medica Group.

Furthest: phase 3, since Feb 12, 20262 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dexa Medica Group20 open or runningphase 3since Feb 12, 2026Jul 15, 2024none ahead

Also a collaborator on its studies: PT Equilab International.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2024First study: phase 2 study in CoughFirst studyNCT06510257 · 60 enrolled · Indonesia
  2. Feb 12, 2026Phase 3 study in CoughPhase 3 reachedNCT07420491 · 144 enrolled · Indonesia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07420491Cough · Indonesia3CompletedOct 3, 2025144
NCT06510257Cough · Indonesia2CompletedSep 30, 202460

How it is read

Names in the registry

  • “Reconyl”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.